賽默飛世爾科技 (TMO) 2017 Q2 法說會逐字稿

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2017 Second Quarter Conference Call.

(Operator Instructions).

I would like to introduce our moderator for the call, Mr. Kenneth Apicerno, Vice President, Investor Relations.

Mr. Apicerno, you may begin the call.

Good morning, and thank you for joining us.

On the call with me today is Marc Casper, our President and Chief Executive Officer; and Stephen Williamson, Senior Vice President and Chief Financial Officer.

Please note that this call is being webcast live and will be archived on the Investors section of our website, thermofisher.com, under the heading Webcasts & Presentations until August 4, 2017.

A copy of the press release of our second quarter 2017 earnings and future expectations is available on the Investors section of our website under the heading Financial Results.

So before we begin, let me briefly cover our safe harbor statement.

Various remarks that we may make about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's annual report on Form 10-K for the year ended December 31, 2016, under the caption Risk Factors, which is on file with the Securities and Exchange Commission and also available in the Investors section of our website under the heading SEC Filings.

While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our estimates change.

Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Also during the call, we'll be referring to certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP.

A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is available in the press release of our second quarter 2017 earnings and future expectations and also in the Investors section of our website under the heading Financial Information.

So with that, I'll now turn the call over to Marc.

Thanks, Ken.

Good morning, everyone.

Thank you for joining us today for our Q2 call.

I'm pleased to report that we had another excellent quarter.

Our team executed very well to deliver great financial performance.

We made terrific progress in advancing our growth strategy, launching new high-impact products and achieving strong results in emerging markets.

And we continue to effectively deploy our capital, announcing our acquisition of Patheon, which will further strengthen our customer value proposition.

Our performance in Q2 continued -- contributed to a strong first half, and we're right on track to deliver another great year.

I'll cover these highlights in more detail during my remarks, starting with our financial results.

First, we delivered another excellent quarter of adjusted EPS growth with a 13% increase to $2.30 per share.

As you know, we have a long track record of consistently delivering strong EPS performance, and we continued that trend in Q2.

Our revenue in Q2 grew 10% year-over-year.

Our adjusted operating income increased 13%.

And we expanded our adjusted operating margin by 50 basis points to 23.3%.

Our margin expansion reflects the continuous impact of our PPI Business System, which is our foundation for operational discipline across the company.

PPI creates competitive advantage for Thermo Fisher Scientific by increasing productivity and quality, which ultimately results in stronger customer allegiance.

Our PPI Business System is a key driver of profitable growth and is a great playbook for optimizing our existing businesses as well as integrating acquisitions.

To summarize the financial results, we achieved another great quarter that led to a strong first half, which puts us where we need to be at the midpoint of the year.

Let me give you some color on our performance relative to our end markets.

They played out as we expected and in line with our full year guidance.

Pharma and biotech continued to be our strongest end markets with growth in the mid-single digits in Q2.

We continued to leverage our unique value proposition with these customers and saw strong performance across our biosciences, chromatography and mass spectrometry businesses as well as our research and safety market channel.

Turning to industrial and applied, we grew here at about the company average in Q2.

Similar to last quarter, we saw a good demand in our research and safety market channel from industrial customers.

And we were encouraged to see a return to growth in our chemical analysis business in the quarter.

Applied markets, particularly environmental and food safety, remained strong as they have for quite some time.

In our other 2 end markets, academic and government, and diagnostics and health care, conditions were similar in Q2 to what we've been seeing for a number of quarters.

We grew in the low single digits in both of these end markets.

Now let me turn to some of our many business highlights we had in the quarter.

As usual, I'll put them in the framework of our growth strategy, which is centered on developing high-impact innovative new products, leveraging our scale in Asia Pacific and emerging markets and delivering our unique value proposition to our customers.

So starting with innovation.

As you will recall, we began the year strong and we increased our momentum in Q2 with a number of significant developments.

Let me give you a few examples from the quarter.

First, the American Society for Mass Spectrometry is always a great opportunity for us to reinforce our leadership, and we proudly celebrated our 50th anniversary in mass spectrometry this year.

The progress we continue to make was very evident at ASMS so I'll mention a couple of the highlights.

For life science researchers, we continue to build on our leading Orbitrap platform, raising the bar in both accuracy and speed to accelerate results in proteomics.

The newly launched Q Exactive HF-X system was designed to improve analysis of complex biological samples and translational research in biopharma applications.

For customers in applied markets, we launched 2 new triple-stage quadruple systems that improved quantitative workflows in clinical research and forensic toxicology.

For example, in our genetic analysis business, we introduced the new SeqStudio Genetic Analyzer.

This is a simple to operate, affordable and cloud-enabled system for customers working in low or mid throughput genetic laboratories.

This launch builds on our leading position across the genetic analysis workflow.

Turning to diagnostics.

We're very pleased to receive clearance from the U.S. FDA for 2 important tests that give clinicians the information they need to make better decisions for their patients.

First, in a significant development, we were granted premarket approval for the first companion diagnostic test using next-gen sequencing to screen for non-small cell lung cancer.

Our Oncomine Dx Target Test can simultaneously evaluate 23 genes associated with this disease and identify patients who may be a match for certain treatments.

We developed the test in partnership with Novartis and Pfizer, and the goal is to expand its use beyond lung cancer in the future.

This is an important milestone in our company-wide effort to advance precision medicine and is a great example of the unique capabilities we have to support this global initiative.

We also received 510(k) clearance to expand the use of our BRAHMS PCT-sensitive cryptor assay to aid in antibiotic therapy decision-making.

What this means is that the assay can help doctors decide when to administer antibiotics to patients with lower respiratory tract infections or when to safely discontinue antibiotics in those patients.

As a specific biomarker for bacterial infection, our PCT test is an effective tool for addressing the challenge of antibiotic resistance.

The second element of our growth strategy is to leverage our scale in APAC and emerging markets.

The headline here is that we delivered another strong quarter, with both China and India delivering double-digit growth.

It's clear that our scale is an important competitive advantage for us, particularly in these regions.

We continue to increase our presence in emerging markets and our teams are effectively leveraging those investments to drive growth.

The good example from the quarter comes from the Middle East, where we strengthened our long-term relationship with the King Abdullah University of Science and Technology in Saudi Arabia, better known as KAUST.

We participated in the opening of the KAUST Center Of Excellence For Electron Microscopy, which is a technology we added through our acquisition of FEI.

The KAUST collaboration is intended to accelerate research by bringing these highly sophisticated tools to local scientists and industries for applications ranging from nanoparticles to Life Sciences.

I'll also add that our electron microscopy business had strong performance again in Q2.

As we approach the anniversary of the FEI acquisition in late September, the integration continues to go very smoothly.

We're running ahead of our year 1 accretion targets and that's driven by the combination of strong growth and synergies.

Longer term, we're on track to deliver our year 3 synergy targets and we're beginning to tap the many opportunities we have with FEI to create tremendous value for our customers.

That's a good transition to the third element of our growth strategy, which is our customer value proposition.

Our agreement to acquire Patheon is the latest example of the significant investments we continue to make to enhance our offering for our customers.

We're really excited about the new outsourcing services we'll gain from Patheon, which will allow us to provide comprehensive support for our biopharma customers from drug development to clinical trials to commercial manufacturing.

When I talk to these customers, the feedback has been very positive.

And they're eager to explore new opportunities to expand our partnerships.

Here's a quick update on the progress we're making as we work towards the close.

The integration teams from both companies are well into the planning phase, so we can hit the ground running at the time of close.

I've been very impressed by the state-of-the-art facilities I've seen and the world-class team I've met during the integration progress -- process.

We've begun to put financing in place and we're moving through the regulatory process.

We're very confident in our ability to close by the end of the year and look forward to officially welcoming our new Patheon colleagues to Thermo Fisher.

Including Patheon, we will have deployed approximately $8.5 billion of capital in 2017.

Our successful capital deployment strategy gives us the ability to create significant shareholder value through a combination of strategic M&A, stock buybacks and dividends.

Let me now turn to our guidance for 2017.

As you saw in our press release, we're raising both our revenue and adjusted EPS guidance for the full year.

Stephen will cover the detail, but at a high level, we're raising our revenue guidance to a new range of $19.71 billion to $19.89 billion, which will result in 8% to 9% growth over 2016.

In terms of our adjusted EPS guidance, we're raising it to a new range of $9.15 to $9.28 for 2017 for 11% to 12% growth over 2016.

Before I turn the call over to Stephen, let me summarize our key takeaways from Q2.

We delivered an excellent quarter, which contributed to a strong first half.

We're successfully executing our growth strategy to create long-term value for our customers and shareholders.

We're right on track at the midpoint of the year and that positions us to achieve an excellent 2017.

With that, I'll now hand the call over to our CFO, Stephen Williamson.

Stephen?

Thanks, Marc, and good morning, everyone.

I'll take you through an overview of our second quarter results for the total company.

And then I'll provide some color on our 4 business segments and conclude with our updated 2017 guidance.

Before I get into the details, let me start with a high-level view of how the second quarter played out versus our expectations at the time of the last earnings call.

As you saw in our press release, we delivered 4% organic growth in Q2 and that was in line with our expectations for the quarter.

FX came in about $50 million less of a headwind on revenue than we'd expected, but was a $0.01 more of a headwind on adjusted EPS due to transactional and nonoperating FX losses in the quarter.

However, despite the additional FX headwind on adjusted EPS, we were still able to finish $0.04 higher in Q2 and would assume at the midpoint of our previous guidance.

This is due to excellent operational performance across the company, including strong volume and pull-through from our FEI electron microscopy business.

So another quarter of very strong execution.

Now let me give you more color on Q2, starting with our total company financial performance.

As you saw in our press release, we grew adjusted EPS in Q2 by 13% to $2.30.

GAAP EPS was $1.56, up 20% from Q2 last year.

On the top line, our reported revenue grew 10% year-over-year.

The components of our Q2 reported revenue included 4% organic growth, 8% growth from acquisitions and a 1% headwind from foreign exchange.

Looking at our growth by geography in Q2.

North America grew about the company average and Europe grew in the low single digits.

Asia Pacific grew in the high single digits, including mid-teens growth in China.

And rest of the world was flat this quarter.

Turning to our operational performance.

Q2 adjusted operating income increased 13% and adjusted operating margin was 23.3%, up 50 basis points from Q2 of last year.

The 50 basis points of expansion was the result of good pull-through from our organic growth, driven by strong contributions from our PPI Business System and volume leverage, which was partially offset by unfavorable business mix, strategic investments and foreign exchange.

Adjusted gross margin came in at 48.3% in Q2.

This represents a contraction of 30 basis points from the prior year, primarily driven by business mix and foreign exchange, partially offset by strong contributions from our PPI Business System.

Adjusted SG&A in the quarter was 20.6% of revenue, which is 120 basis points favorable to Q2 2016, primarily driven by business mix and the impact of acquisitions.

R&D expense came in at 4.4% of revenue, up 40 basis points versus Q2 last year.

R&D as a percent of manufacturing revenue increased 6.7%.

This is 50 basis points higher than Q2 2016, primarily due to the impact of FEI's more significant R&D spend.

Looking at our results below the line, net interest expense was $116 million, up $10 million from Q2 2016.

Adjusted other income and expense was a net expense in the quarter of $7 million, which is $13 million unfavorable versus Q2 2016, which was driven primarily by changes in nonoperating foreign exchange.

Our adjusted tax rate in the quarter was 13.1%, which is 40 basis points lower than last year and right in line with our expectations for the quarter.

The average diluted shares were 393.3 million, down 3.4 million year-over-year, mainly as a result of share buybacks, partially offset by option dilution.

Turning to cash flow and the balance sheet.

Cash flow from continuing operations for the first half of the year was $1.21 billion.

And free cash flow was $1.03 billion after deducting net capital expenditures of $180 million.

We ended the quarter with $650 million in cash and investments.

During Q2, we completed $250 million of share buybacks and paid $60 million in dividends.

Our total debt at the end of Q2 was $16.8 billion, down $300 million sequentially from Q1.

And our leverage ratio at the end of the quarter was 3.4x total debt to adjusted EBITDA, down from 3.6x at the end of Q1.

In wrapping up my comments in our total company performance, we continue to see the good year-over-year improvement in ROIC, even net of the impact of recent acquisitions.

Our trailing 12 months adjusted ROIC at the end of Q2 was 10%, up 20 basis points over Q2 2016.

Now let me provide you some color on the performance of our 4 business segments.

Starting with the Life Sciences Solutions Segment, reported revenue and organic revenue both increased 3% in Q2.

In the quarter, our biosciences business delivered particularly strong growth.

Q2 adjusted operating income in the segment increased 15%.

And adjusted operating margin was up 340 basis points year-over-year to 31.9%.

In the quarter, we saw very strong productivity and volume pull-through, partially offset by business mix, strategic investments and the dilutive impact of acquisitions.

In the Analytical Instruments Segment, which includes our new FEI electron microscopy business, reported revenue increased 47% in Q2 and organic revenue growth was 6%.

In the quarter, we had strong growth in chromatography and in the mass spec businesses.

And it was encouraging to see the chemical analysis business return to positive growth, as Marc mentioned earlier.

Q2 adjusted operating income in Analytical Instruments grew 61%.

And adjusted operating margin was 20%, up 170 basis points year-over-year.

In the quarter, we continued to see a positive impact from electron microscopy business as well as strong volume leverage and productivity.

This is partially offset by FX and strategic investments.

Turning to the Specialty Diagnostics Segment.

In Q2, total revenue grew 1% and organic revenue growth was 2%.

Our transplant diagnostics business delivered particularly strong growth in the quarter.

Adjusted operating income decreased 1% in Q2.

And adjusted operating margin was 27.3%, which represents a contraction of 60 basis points from Q2 of the prior year.

Adjusted operating margin was positively impacted by good productivity, but this was more than offset by strategic investments and business mix.

Finally, in the Lab Products and Services Segment, Q2 reported revenue increased 4% and organic revenue growth was 5%.

In the quarter, our channel business delivered particularly strong growth.

Adjusted operating income in the segment decreased 5%.

And adjusted operating margin was 13.8%, down 130 basis points from the prior year.

Adjusted operating margin benefited from both productivity and volume leverage.

However, as expected, this was more than offset by the impact of the unfavorable business mix driven by our biopharma services business, which was impacted by the discontinuation of a large Phase III clinical trial last year, as we mentioned last quarter.

With that, I'll now move on to our full year 2017 guidance.

As you saw in our press release, we are raising our guidance.

Let me walk you through the details, starting with revenue.

We continue to expect to deliver 4% organic revenue growth for full year 2017.

The midpoint of our revenue guidance is increasing $190 million.

Of that increase, $160 million reflects the less adverse foreign extension environment and $30 million reflects an improvement in the outlook from our FEI acquisition.

In terms of adjusted earnings per share, there are 2 key changes to our guidance.

First, we're increasing the midpoint of our guidance by $0.065 to reflect our strong Q2 operational performance and the less adverse FX environment for the year.

And second, as you may have seen, we've started the process of securing permanent financing for the Patheon acquisition.

And last week, we completed a $3 billion European bond offering.

For 2017, the interest on this new debt will equate to approximately $0.05 of adjusted earnings per share, and we factored this into our revised guidance.

As is our usual practice, our guidance does not include any future acquisitions or divestitures and therefore does not include Patheon or any related future financing activities.

And finally, with another quarter of great performance behind us, we're narrowing our revenue guidance range to $180 million and narrowing our adjusted earnings per share range to $0.13.

Summing this all up, the increased 2017 revenue guidance is now a range of $19.71 billion to $19.89 billion, which would represent 8% to 9% growth versus 2016.

We expect acquisitions to contribute just under 5% to our reported revenue growth in 2017.

And foreign exchange is expected to be a headwind of $90 million or 0.5%.

And as I mentioned previously, 4% organic growth.

In terms of adjusted earnings per share, our increased 2017 guidance is now a range of $9.15 to $9.28 with a midpoint of $9.215.

This represents growth of 11% to 12% versus 2016.

We now expect the headwind from foreign exchange of $0.15 or just under 2%.

That is $0.02 less of a headwind than our previous guidance.

Excluding the impact of foreign exchange, this would represent adjusted earnings per share growth of 12% to 14%.

A few other details behind our revised 2017 guidance.

We now expect 50 to 60 basis points of adjusted operating margin expansion year-over-year compared to the 40 to 60 basis points in our previous guidance.

Foreign exchange is now a 10 basis point headwind for the year compared to a net neutral in our previous guidance.

However, this is being more than offset by the strong operational performance.

We're expecting net interest expense to be about $480 million, and the other income and expense to be a net expense of $12 million.

We continue to forecast our adjusted income tax rate to be 13.3% for the year.

We've completed $750 million of share buybacks this year.

And given the pending acquisition of Patheon, at this point we do not expect any additional buybacks in 2017.

We continue to assume we'll return approximately $240 million of capital to shareholders through dividends in 2017.

And full year average diluted shares are estimated to be in the range of 393 million to 394 million, consistent with our previous guidance.

We're assuming net capital expenditures to be approximately $500 million, no change from the previous guidance.

And we continue to expect about $3.15 billion of free cash flow for full year 2017.

And finally, in terms of phasing, we're expecting organic growth to be relatively even over the remainder of the year.

For adjusted earnings per share, we expect that if we phase across the remaining 6 months of the year in a similar way to the same period in 2016.

As always, in interpreting our revenue and adjusted EPS guidance ranges, you should focus on the midpoint as the most likely view of how we see results playing out.

So in summary, we delivered another strong quarter in Q2, which positions us well at the halfway point to achieve our full year 2017 financial goals.

With that, I'll turn the call back over to Ken.

Thanks, Stephen.

Dan, we're ready to open it up to questions.

(Operator Instructions) Our first question today comes from the line of Ross Muken with Evercore ISI.

So Marc, the company has had a remarkable ability to sort of identify assets before inflections in their business.

Obviously, it happened with Life Tech and now we're seeing it with FEI.

I account the core growth there was north of 20%, so that business is seemingly on fire.

I mean, I guess, as we think about that and then eventually Patheon rolling into the organic over time, what would it take from an end market perspective or what mix or shift the businesses would have to happen for organic growth not to ultimately accelerate from here?

And I guess, as you look at sort of the end markets as they trended over the balance of the quarter, what, if anything, should we keep in mind as sort of an offset to this because it seems like versus where we were several years ago, the business is sort of poised and now be at kind of the upper end of the peer group from a core growth perspective?

Ross, thanks for the question.

I guess, a few thoughts.

One is the FEI acquisition is performing very well.

The integration is an intensive effort and the team really has not been distracted.

So they're doing a good job of integrating the business, but they're also delivering good growth and good bookings.

And that's a testament to the strength of the team and the proven integration processes we have.

So that's obviously a positive.

As I look towards the end markets just kind of broadly in terms of growth, at a high level, we finished the first half at 4%.

Each quarter was 4%.

We maintain our guidance at 4% for the year.

Obviously, we're going to strive to drive to the best possible performance.

But I'd say one of the catalysts from here in terms of stronger momentum as you think about '18 and beyond, or even second half and beyond, it's going to be -- let's get a U.S. government budget in place for '18, right?

It was good to get the '17 budget.

It was good to see NIH funding increased.

We'll continue to educate Congress, but feel good about that process.

So if we can get -- skip a continuing resolution, get a budget in place, that would be -- would clearly continue some momentum in academic.

And then, at least from our own perspective, we don't really wait for the end markets.

It's the actions we take.

So we have a lot of effort around product development that put us in position to be in the higher ends of our growth target.

So that's how I would think about it, Ross, at a high level.

And maybe just on sort of the pharma end market, if you -- you gave a few points that were kind of helpful.

I mean, as you think about kind of the pacing there and what we've seen in sort of different subsegments of that market, I know I think coming into the year, you guys have sort of talked about growth rates consistent with what we've seen or maybe they've been slightly better.

But how are you thinking about sort of the exit velocity of that business out of the quarter or that sort of segment and then some of the moving parts there in terms of how that's likely to trend?

Yes.

So Ross, let me give you a relatively comprehensive view on pharma/ biotech.

I know it's an area of interest.

First is pharma/ biotech is our strongest end market.

We performed very well in the quarter.

We grew a couple points higher than the company average serving that market.

In terms of what drove that growth, first, as I mentioned last quarter, our clinical trials business was impacted by the discontinuation of a large Phase III study and that headwind will sunset in Q4.

Bioproduction growth was a bit more muted this quarter, and you'd seen that across the industry.

The super important point to highlight is that our business is serving the research customers.

Biosciences, chromatography and mass spectrometry and the channel, they all grew incredibly strongly in the quarter.

So it's another great quarter for us and our value proposition continues to resonate very well with the customer base.

Your next question comes from the line of Tycho Peterson with JPMorgan.

Marc, maybe I want to pick up on that last point on the Life Sciences Solutions.

It was the slowest growth that we've seen in a little while for that segment.

Can you maybe just talk on your outlook there and some of the comments you've previously made on bioprocessing a little bit softer?

Yes, sure, Tycho.

Thanks for the question.

So when you look at Life Sciences Solutions, we had 7% growth in Q1, 3% growth in Q2, 5% average for the first half.

I would focus on the 5% average.

And when you look at -- Easter played a little bit of an effect with a little bit of a benefit in Q1, obviously, a little bit of a headwind in Q2.

And when I look at the outlook for the business, it looks good.

When you get into the details of why was growth a little bit slower, particularly in Q2, holding aside timing and those things, bioproduction was a little bit more in line with the industry.

It was growing in this particular quarter.

And the biosciences business continues to do very well.

So that's really the factors from Life Science Solutions.

And then following up on the FEI question, how much of the inflection we're seeing now is on the Cryo-EM side versus the semi-cycle picking up for that business?

So when you look at the performance of the Cryo-EM, that continues to go extremely well with strong growth in revenue and strong growth in bookings.

The material science business, which includes basically everything else, semiconductor and all the other applications for electron microscopy clearly is continuing to be very strong.

And you're seeing the benefit of a strong pipeline in semiconductor as well as good performance in material science applications elsewhere.

So that business is performing at a very strong level.

Okay.

And then just last one on capital deployment.

With the equity issuance component to the Patheon deal, it seems like the door is still open to potential do another acquisition in the near to intermediate term.

Can you maybe just talk on your appetite and willingness to do another deal?

Yes.

From our perspective, our #1 priority is to run the businesses that we have, right, and run them very well.

And we're excited about our portfolio.

And we're looking forward to closing Patheon and successfully integrating that and creating value for our customers and our shareholders.

We continue to have an active pipeline of smaller bolt-on transactions and we'll continue to look at those transactions.

And should the right ones make sense, you'll continue to see us to do a modest level of M&A from that perspective.

Your next question comes from the line of Derik De Bruin with Bank of America.

The Specialty Diagnostics business for the second quarter in a row, it's been a little bit below what we had calculated.

And I think we're trying to sort of fathom that given that the patient visit data looks pretty decent from IMS and some other ones.

Can you sort of talk us through what's going on in the Specialty Diagnostics business?

And is there something going on from a health care perspective and people worried about health care reform and everything like that?

Can you sort of walk us through -- or people not buy -- or worry about PAMA or people not buying instruments or things like that, that is potentially slowing the market down?

Yes, Derik, it's a very good question.

So let's delve into Specialty Diagnostics a little bit.

It's -- it was low single-digit growth in the quarter consistent with what we've seen over the last few quarters.

The 2 businesses that had very strong growth were our biomarker business and our transplant diagnostic business.

And every other business in that portfolio was stable and all grew modestly.

So if you kind of look at it from a product range perspective, 2 really strong growing businesses.

And then the rest of the portfolio, stable and modest growth.

When you look at geographically, really, it was Europe that was not robust.

North America is fine.

And when you look at the activity, it seems that there are many bright spots in Europe, but it seems that health care was relatively modest from that perspective.

So I wouldn't be reading too much into the ACA and PAMA and those things.

That's not really been a big factor.

We are taking a number of actions to strengthen the growth prospects of that business.

Obviously, our Specialty Diagnostics business is incredibly profitable.

It's been incredibly stable.

It has great brand and customer allegiance.

And it's all about taking a low single-digit growth and making it faster.

You probably saw that we introduced, but did not launch yet, our Cascadia mass spectrometer and we will also introduce that at AACC.

That is intended for being launched sometime during the course of 2018, so it's not going to affect any revenue this year.

But we want customers to get into the budget cycle.

So we're making progress, but we obviously -- we're on plan to launch it this year anyway.

But we're just kind of working our way through that process, which should help growth over time as well.

Great.

And just one follow-up question.

You've called out in LTS the channel business was quite strong, I mean, considering that everyone's worried about Amazon in the world today.

Could you elaborate on how strong the channel business was and just give us a little bit more detail?

The channel was very strong in the U.S. It was very strong in Europe.

It was very strong in biotech and pharma.

And it was very strong in industrial.

There were no weak spots in the channel business.

Team is doing a great job.

And we take Amazon very seriously, and we always have, and it's our job to manage through that.

We're making big investments in our e-commerce capabilities, big investments in supply chain, the great personnel we have working in customer labs every day that really handles the hazardous goods or refrigerated materials.

And the customer allegiance we have in the channel is fantastic.

So that's how I would characterize it.

Your next question comes from the line of Doug Schenkel with Cowen & Company.

I just want to go back to Life Sciences Solutions for a minute.

You've talked a bit about bioprocessing growth coming back to the industry average.

Is that just a function of the inherent lumpiness of that business?

Or is there something different going on fundamentally than maybe a quarter or 2 ago?

And also within Life Sciences Solutions, I believe this is the first quarter where Affymetrix is fully in organic growth.

I'm curious how integration is going there and if Affy was actually dilutive to Life Sciences Solutions organic growth in the quarter.

Doug, thanks for the questions.

So yes, so bioproduction is definitely a lumpy business.

And the long-term prospects for bioproduction is fantastic.

When you think about the demand for biologics, biosimilars, vaccines in the pipeline, we're very bullish.

One of the leading indicators we have is our biosciences business serves the research customer base with those technologies, especially media and sera.

And that business is incredibly robust, so the activity level is very strong.

So nothing is changing on the long-term outlook.

There's some lumpiness in Q2.

While it grew reasonably, it was softer than the very -- toward growth that we had the last few quarters.

And we would expect that growth will pick up over time there.

So that's our view on bioproduction.

On the microarray business, really good news.

We've always been transparent with everything and we started out slower when -- after the acquisition of that business.

We had good growth in the microarray business.

We had good growth in the e-biosciences business.

Synergies have been very strong.

And when you look at the full year accretion in 2017, I am really excited that the team has put us right back on track for achieving the deal model goals for 2017 after starting off a little bit soft.

The team has done a great job.

So very good growth in microarrays in the quarter.

Okay.

Pivoting to Europe, I think you guys grew low single digits in Europe.

That's a bit lower than the growth rate we've seen from you over the past couple of quarters.

Some of your peers have actually talked a bit about higher growth in Europe.

Could you just talk about how Europe is going by end market?

And what's factored into guidance in terms of your expectations for the rest of the year?

Yes, I think Europe, when I look at performance in Europe, Easter is obviously going to be the swing -- big swing factor.

I just did a review with the team, our European leadership yesterday, and they feel good, right?

So Q1 was strong.

Q2 was more modest growth.

And that's really the shift of where the holiday was.

And when they look at their outlook for the balance of the year, it's right in line with growth that should be for the full year, just below the company average.

Which is what we've guided to initially.

So I don't see Europe as a major story.

If you go down to the end markets, I would say that the diagnostic business across is a little bit softer than we originally would have expected.

And the rest of the segments are a little bit stronger, would be the take.

Okay.

One last one.

Just want to make sure, I think, this is the case, right?

I just want to make sure that you still are assuming mid-single digit to high single-digit biopharmaceutical end market growth in your full year guidance.

Yes.

So the last few years, we've started out our guidance for biopharma end market being mid-single to high single-digit growth.

And that continues to be our outlook for this year, so no change.

And when you look at the first half, we're right in the middle of that range at this point.

Your next question comes from the line of Jack Meehan with Barclays.

I want to dig a little bit more into the Analytical Instruments performance, another pure organic there.

Could you talk about the trends throughout the quarter?

Good to hear about chemical analysis, but just how things trended and the outlook there for the rest of the year.

Yes, Analytical Instruments business, it's a really positive story.

And if you think about for a lot of quarters, like many, we've talked about how strong the chrome and mass spec business was and that it was offsetting weakness in chemical analysis.

Chrome and mass spec business was very strong in the quarter.

And it was particularly strong serving the biotech and pharmaceutical customers, so that business is really humming.

And chemical analysis returned to growth, which is a great.

And we saw both our long-cycle and short-cycle revenue to the industrial customer base pick up.

And bookings continue to be positive.

So that's good.

And Jack, this is Stephen.

I'd just add some on the chemical analysis side that we've been seeing that trend for a while in terms of the bookings coming.

And it's good to see that both the short-cycle and the long-cycle aspect of that business are picking up and delivered positive organic growth in Q2.

And then obviously, in the fourth quarter, the last week of September and the fourth quarter, the electron microscopy business will become part of the organic growth calculation for those businesses as well.

So Analytical Instruments team is doing a really good job and the results demonstrate that.

Great, that's helpful.

And then one for Stephen.

I think it's a similar question I asked last quarter, just the margins in LPS.

Could you elaborate a little bit more there?

Is it just the biopharma services contract you talked about?

Or are there any other mix changes in the channel?

Yes, it's really the driver of the biopharma -- the clinical trials business, the biopharma services.

It's the same driver as last quarter in terms of the pressure there and that will sunset at -- by Q4.

Outside of that, would margins have been up in the quarter in that segment?

Yes.

Marginally, yes.

But it's not the same.

We'll see significant margin expansion over time.

But yes, that's correct.

Your next question comes from the line of Timothy Evans with Wells Fargo Securities.

Marc, on the large clinical trial cancellation, if that had not occurred, would you be calling out, say, something more like mid to high single-digit growth this quarter in the pharma end market?

Is it big enough to skew things that much?

Yes.

It would have been high single-digit growth right around that range.

Yes.

Oh, it would have been high single-digit growth without that cancellation?

Yes.

Okay, great.

And then just on the EPS bridge, I want to make sure that we have that on the guidance.

So it's going out $0.065 at the midpoint.

It sounds like that's absorbing $0.05 of interest.

And then you've got $0.02 FX.

So basically, we're talking -- is that right?

Let me just clarify.

So the $0.065 includes the FX piece.

So it's operational performance in Q2, plus the change in FX for the year.

My guidance is $0.02.

That gets you the $0.065 increase.

And that's offset by $0.05 dilution from the interest cost on the European bond offering.

The net of that midpoint is $0.015.

Your next question comes from the line of Steve Willoughby with Cleveland Research.

Just -- was wondering if you could comment a bit more on what you're seeing in the academic end market.

I believe, and I might have missed some of it, you commented that it was a little bit weaker this quarter.

Just trying to see what you saw, both, I guess, from academic and government, both in the U.S. and in Europe And what your expectations are for the rest of the year.

Yes, actually academic and government, while still low single digits, it wasn't weaker.

It actually was slightly better than Q1.

And when you look at, actually, North America was a bit better.

So I think the fact that you got a 2017 budget, it showed the increase in NIH, that's starting to flow into the results.

Kind of geographically, China was good as well and Europe was a little bit softer.

So -- and it's probably mostly timing between Q1 and Q2.

Okay.

And then just one follow-up question for Stephen.

Within the guidance bridge that you were talking about there, the operational performances, can you describe or quantify how much of that is kind of stronger growth from FEI versus the underlying base business?

It's approximately $0.03 more from FEI and $0.015 from the base business.

Your next question comes from the line of Dan Arias with Citigroup.

Marc or Stephen, to your points on chemical analysis, does that feel like that business should stay positive in the back half of the year just given the way both things are shaping up?

Yes, we don't forecast by each of our businesses, especially at that level.

But clearly, the trends are positive and that's -- I think that's a reasonable assumption you're making.

Okay.

And maybe just on China, curious if you'd be willing to parse out the growth that you're seeing or you're expecting this year if we just look at Life Sciences, the Life Sciences piece versus the applied industrial business.

Just be helpful to understand the relative contributions there on the 2 sides of the equation.

Yes, so we had mid-teens growth in China.

We had strong bookings.

The outlook is good for the full year.

That's been -- trends continue.

Clearly, our customers value our scale and the experience that we create because of that scale.

In terms of more color, I would say, generally, the business across pharma and biotech, life science research, those typically is pretty strong.

Industrial is recovering and growing.

Applied is very strong there, as is health care and diagnostics.

So it's fairly broad-based, right, in terms of what the growth is in China.

Okay.

And just finishing on your comment on the outlook.

Is it double-digit growth rate for the year sort of assumed in guidance for China?

Yes.

So our guidance assumes basically double-digit growth for China.

As you know, China is a fastest-growing market and has been.

As a market, we think the outlook is very strong.

Yes, I think the bookings profile is very positive.

Your next question comes from the line of Isaac Ro with Goldman Sachs.

It's actually Joel in for Isaac.

Just to go back on the FEI question maybe just focusing it on the Cryo-EM opportunity, can you maybe comment on whether you -- just given the underlying academic sort of funding environment if it -- has there been wallet share dynamics or other technologies in the lab that you've been sort of gaining some share from that contributed to the growth in the first half of the year?

I think that from my interactions with customers around Cryo-EM, and there's been a number -- wow, what an amazing technology.

I mean, the enthusiasm across the customer base is huge.

And it's making them rethink other large investment areas that might have traditionally gotten that funding.

So I have not heard funding.

In all of the discussions, funding has not come up as an issue, meaning that this is profound enough that customers will go out and get the money.

And in those areas where there's lots and lots of funding, then that's one way.

And if there are other areas where funding is more muted, they're probably taking it from other technologies and, likely, from technologies that we don't provide.

So we're not cannibalizing ourselves.

Great.

And then just maybe one on the P&L.

Looks like there's been a little bit of an uptick in R&D expense in the first half of the year.

Just how should we be thinking about that line item throughout the remainder of 2017?

Yes.

So in terms of R&D, the driver of the change as a percentage really is the inclusion of FEI.

It has a higher-than-average cost of company spend in R&D.

We're continuing to invest in that business, so that dynamic will play out in Q3.

And then it would be in the comps in Q4, overall.

This business actually -- as among Q3 for FEI, just as a reminder that we have the step period, which is very profitable step period in Q3 last year and that will be in our comps in terms of margin expansion as you look at the second half of the year for the company as a whole.

So it has a little bit of a drag on Q3 margins.

Your next question comes from Paul Knight with Janney Montgomery.

Marc, could you talk about FEI?

Was the growth there a component of the semiconductor cycle?

Just the level of the breakout of that growth would be helpful.

Sure.

So Paul, when you look at the FEI business, the growth was very, very robust in the Life Science applications, in the semiconductor applications.

And we had good growth in the remaining material science applications.

So the business would have delivered strong growth, even if semiconductor was more muted.

But semiconductor was a very strong and bookings were very strong.

So that's very positive in terms of how the business is performing.

And then regarding China, do you think -- do you see budget cycles?

Or with the Five-Year Plan now in place, is this -- say, is it a consistent rollout this year?

Yes, it's been a very good now for quite a number of quarters, right?

Since the beginning of 2015, we've had very strong growth every quarter in China.

And the outlook continues to be quite good.

We're very aligned with the Five-Year Plan.

As you know, China has a big focus on environmental protection, big focus on food safety and certainly, around expanding the health care market as well -- or health care capabilities.

So we're seeing broad-based growth.

And we would expect China to continue to be our fastest-growing end market.

Your next question comes from the line of Brandon Couillard with Jefferies.

Just a couple of housekeeping questions for Stephen.

On Patheon, number one, would you care to update us on what you view as the anticipated accretion in year 1 now that the debt financing is in place?

Number two, what are the next steps or exact approval milestones needed before closing?

And thirdly, can you just sort of explain the rationale with keeping the interest expense in the core EPS number rather than backing it out before the close?

So I'll do part of it and Stephen will do part of it.

I'll do the path to close and Stephen will do the 2 financial questions.

In terms of the path to close, we obviously got our U.S. clearance quickly.

The European Union accepted the filing, which means that they start the regulatory process, which is -- which will go on during the course over the summer.

And then the last of the regulatory filings, which has a more variable range on when it will wrap up is Brazil, which we're working through.

And then we need to have the shareholder vote and the tender process, which we're working through as well.

So we feel very confident that the transaction will close before the end of the year or by the end of the year.

And we're just working to work that through expeditiously as possible.

Yes.

And in terms of the financing, obviously, we're working to ensure that we've got the permanent financing in place for the timing of the deal close, whenever that may happen.

You saw the first part of that being executed last week, which was the European bond offering that we did.

That was $3 billion of a debt raise.

So that's just the first element.

We got additional debt to raise.

And we've got an equity element as well.

So -- and we'll still continue to work the rest of those elements and those -- details of those will be public as we execute those.

In terms of the guidance, so we've actually completed the European bond offerings.

It was a known event, so I included it in the guidance for the full year.

So that's kind of a consistent approach in the way that we've approached and kind of pending acquisitions in the past.

So we're treating Patheon and its related financing in that consistent away.

So as things will crystallize, I put them into the guidance.

And our final question will come from the line of Catherine Schulte with Robert W. Baird.

You mentioned getting a U.S. budget in place would be a positive.

What kind of size of NIH funding increase would you need to see to consider it a good enough outcome?

Yes, when I was with members of Congress fairly recently, I think the strong support for a continued funding of NIH and continued growth in fund -- funding, and we'll continue to educate the importance of that.

Things like the 21st Century Cures is obviously a positive.

What -- to us is what we're focused on is to avoid the continuing resolution, which obviously creates some level of uncertainty and freezes budgets.

The House is talking, I think, $1 billion increase.

And I think the Senate might be talking a little bit more.

The exact number, to me, is less of a focus than an increase in funding and getting a budget done.

Okay.

And can talk about your organic growth assumptions by division for the back half of the year?

Really, I think in terms of the full year outlook, it hasn't changed in terms of our initial guide.

So I think Life Sciences Solutions and Analytical Instruments will be the faster-growing businesses out of the 4. So that's really the way to think about the speed of growth for the respective businesses for the full year.

So let me just wrap it up briefly.

As we reflect on where we are, we're very pleased to have achieved a strong first half.

And we're very well positioned to deliver another great year.

And of course, thank you for your support of Thermo Fisher Scientific.

We look forward to updating you on the Q3 call.

Thanks, everyone.

Thank you to everyone for attending.

This will conclude today's conference call, and you may now disconnect.